Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
New in the 10-K 17 paragraphs with nothing like them in the 10-K filed Feb 27, 2025 New in the 10-Q 14 paragraphs not in the 10-Q filed Aug 4, 2026 10-Q against the 10-K 0 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 27, 2025. A box jumps to the paragraph as filed, below.

17 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

17 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 27, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

•the costs associated with maintaining and growing our transplant logistics capabilities, including by means of attracting, training and retaining pilots, and the acquisition, maintenance, or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments;

Read in the 10-K

•the cost of constructing research and development and manufacturing facilities in Italy;

•the costs related to establishing and relocating to a new long-term global headquarters to accommodate the growing scale and complexity of our business;

Read in the 10-K

In order to manufacture the OCS in quantities sufficient to meet our anticipated commercial opportunity, we will need to continue to increase our manufacturing capabilities and retain third parties to sterilize our products. We anticipate that our new

Read in the 10-K

Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs. Conversely, if we underestimate customer demand for our products or our own requirements

Read in the 10-K

As part of our services offered under our NOP, we have acquired a fleet of fixed-wing aircraft. All of the aircraft we currently operate are standardized variants of a certificated model produced by a single manufacturer. Parts and services from this manufacturer

Read in the 10-K
Show the other 7

We may experience disruptions to our business as a result of the relocation of our headquarters and general expansion of our operations.

We may experience disruptions as we continue to expand our operations and facilities and execute on our growth strategy. In January 2026, we entered into a lease agreement with the intent to move our headquarters to a larger space in Somerville, Massachusetts. We intend to renovate the facility before moving our operations, including manufacturing, to this facility. The process of moving our business, opening new facilities and bringing operations online at this new site is inherently complex and is not part of our day-to-day operations. The relocation and expansion of our headquarters and the opening of any additional new facilities, including our planned expansion in Italy, may cause significant disruption to our operations, divert management attention and resources and involve significant costs, all of which could have a material adverse effect on our business, financial condition and results of operations. The relocation of our headquarters and any additional facilities that we seek to open may take longer than anticipated or may not proceed as planned, and the expected benefits may be less than anticipated.

Read in the 10-K

We are expanding our operations outside the United States, which increases operational complexity and may require significant management attention and resources. Our international operations involve increased logistics and supply chain complexity, foreign customs and trade requirements, and reliance on third-party service providers, which may result in delays or increased costs. Operating internationally also exposes us to legal and compliance risks, as well as differing healthcare systems and reimbursement frameworks that may limit adoption of our OCS technologies, NOP services or related offerings or reduce expected revenues and margins, If we are unable to effectively manage these risks, our business, financial conditions and results of operations could be materially and adversely affected.

Our use of artificial intelligence, or AI, and other emerging technologies could adversely impact our business and financial results.

We currently make limited use of AI technologies in our operations, and we may continue to explore further use cases. The rapid advancement of these technologies presents opportunities for us in research, manufacturing, commercialization, and other business endeavors, but also entails risks, including that AI-generated content, analyses, or recommendations we utilize could be deficient, that our competitors may more quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technologies increases regulatory, privacy, cybersecurity and other significant risks. In addition, any disruption or failure in the AI functionality we incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our product offerings. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs on us and limit our ability to effectively develop, deploy or use AI technologies. Furthermore, if we are unable to effectively manage the use of AI technologies by our employees and service providers, our confidential information, intellectual property and reputation could be put at risk. Failure to appropriately respond to this evolving landscape may result in reputational, competitive and business harm as well as litigation and regulatory action and fines, penalties and expenses related thereto.

Read in the 10-K

financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete. Patent litigation and other proceedings may also absorb significant management time.

Read in the 10-K

denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to commercialize our products.

Read in the 10-K

In addition to these MS-DRG-based payments, Medicare reimburses transplant centers for “reasonable and necessary” organ acquisition costs, which are considered “pass-through” costs distinct from the prospective payment system, and are not based on the payments for the applicable MS-DRG. Pass-through organ acquisition costs include services required for the acquisition of an organ,

Read in the 10-K

HRSA continues to implement efforts to improve and modernize the OPTN, including enhancements to patient data on organ procurement, expanded transparency through a publicly accessible data dashboard for allocation out of sequence (AOOS) events, expanded outreach and financial support for living organ donors, and a new OPTN fee collection process whereby HRSA directly collects and distributes patient registration fees under authorities originally granted by the 2025 Full-Year Continuing Appropriations and Extensions Act and extended by the 2026 Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act. The impact that HRSA's initiatives and the Securing the U.S. Organ Procurement and Transplantation Network Act may have on our business, including on our NOP, is uncertain at this time.

Read in the 10-K

Congressional disagreement over the federal budget and the maximum amount of debt the federal government is permitted to have outstanding (commonly referred to as the “debt ceiling”) caused the U.S. federal government to recently shut down. Prolonged government shutdowns impact us and our customers, vendors and others we do business with. During a U.S. government shutdown, certain regulatory agencies, such as the FDA, FAA and the SEC, have had to furlough critical FDA, FAA, SEC, and other government employees and stop critical activities. In addition, the current administration has stated that it could eliminate jobs at federal agencies. Furthermore, although air traffic controllers are deemed to be essential employees who are required to continue to work during a government shutdown, in past shutdowns, including the most recent shutdown, air traffic controllers have more frequently called out of work, creating staffing shortages that affect flights and which could impact our aviation services.

Product development and regulatory activities depend on the continuity and capacity of the FDA and other health authorities. Disruptions at the FDA and other agencies may slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in the past as a result. In addition, government funding of the FDA and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. If there are future shutdowns, our business, financial condition, operating results, cash flows or prospects could be adversely affected.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 5, 2026 that were not in the one before

New in the latest 10-Q

14 paragraphs in the 10-Q filed Nov 5, 2026 with nothing like them in the 10-Q filed Aug 4, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

• the ability to integrate our completed or future acquisitions, joint ventures, and strategic investments, including PAD Aviation service GmbH (“PAD Aviation”);

Read in the 10-Q

• changes in our mix of product and service revenue and the resulting effect on our gross margin;

Read in the 10-Q

Financial statements and notes

operating activities: Depreciation and amortization expense 32,945 19,717 Stock-based compensation expense 31,155 27,466 Deferred taxes 10,756 — Non-cash interest expense 13,936 2,374 Non-cash operating lease expense 1,920 1,547 Unrealized foreign currency transaction (gains) losses 765 (1,481) Loss on disposal of fixed assets 145 80 Changes in operating assets and liabilities: Accounts receivable (28,067) 17,532 Inventory (19,357) (1,185) Prepaid expenses and other current assets (6,949) (4,819) Other non-current assets (233) (10) Accounts payable (2,079) 2,045 Accrued expenses and other current liabilities 7,722 10,728 Deferred revenue (1,407) 1,543 Operating lease liabilities (2,476) (2,118) Net cash provided by operating activities 77,846 158,327 Cash flows from investing activities: Purchases of property, plant and equipment (52,149) (43,737) PAD Aviation investment, net of cash acquired (5,310) — Net cash used in investing activities (57,459) (43,737) Cash flows from financing activities: Repayments of long-term debt (5,000) — Proceeds from issuance of common stock upon exercise of stock options 4,199 10,647 Proceeds from issuance of common stock in connection with employee 3,935 3,249

Read in the 10-Q

On July 1, 2026, the Company, through its wholly owned subsidiary TransMedics GmbH, completed a strategic investment in PAD Aviation service GmbH (“PAD Aviation”), a Germany-based private aviation operator. The investment was made pursuant to a share purchase agreement under which TransMedics GmbH acquired a minority interest in PAD Aviation and all remaining interest was transferred by the sellers directly to a Netherlands Stichting (“PAD Aviation Partner”). The investment supports the Company’s ongoing efforts to build a dedicated organ transplantation air and ground logistics network in Europe.

Read in the 10-Q

The Company evaluated PAD Aviation under the variable interest entity (“VIE”) model and determined that PAD Aviation is a VIE. The investment in PAD Aviation has been made for it to provide aviation services principally on behalf of the Company, and the Company, through these arrangements with PAD Aviation, has the power to direct the activities that most significantly affect PAD Aviation’s economic performance. The Company also has the right to receive benefits and the obligation to absorb losses that could potentially be significant to PAD Aviation. Accordingly, the Company is the primary beneficiary of PAD Aviation and has included PAD Aviation in its condensed consolidated financial statements since the investment date. The consolidation of PAD Aviation for financial reporting purposes does not reflect legal ownership or control of PAD Aviation for purposes of applicable aviation regulations.

Read in the 10-Q
Show the other 9

The investment in PAD Aviation was accounted for as a purchase of a business under ASC Topic 805, Business Combinations. The preliminary purchase consideration of $7.4 million, net of cash acquired, reflected an upfront cash payment, deferred consideration and working capital adjustments.

Read in the 10-Q

The Company’s condensed consolidated financial statements reflect the preliminary allocation of the purchase price to the assets acquired and liabilities assumed based on fair value as of the date of the investment. The Company’s estimate of preliminary purchase consideration is subject to change upon finalizing working capital adjustments. The following table summarizes the allocation of the preliminary purchase price (in thousands):

Read in the 10-Q

The identifiable intangible assets consist of customer relationships and a trade name and are being amortized to selling, general and administrative expenses over their estimated useful lives of seven years. Goodwill was recognized for the excess purchase price over the fair value of the net assets acquired. Goodwill is primarily attributable to the assembled workforce of the acquired business (which is not eligible for separate recognition as an identifiable intangible asset) and anticipated synergies. Goodwill from the investment is included within the Company’s one reporting unit and in the Company’s enterprise-level annual review for impairment. Goodwill resulting from the investment is not deductible for tax purposes.

Read in the 10-Q

The Company incurred total transaction costs of $5.1 million for third-party professional services utilized for the investment, which are included within selling, general and administrative expenses in the condensed consolidated statements of operations. The operating results of PAD Aviation have been included in the Company’s condensed consolidated financial statements beginning on the investment date. Pro forma results of operations for the investment have not been presented as they are not material to the Company’s condensed consolidated results of operations.

Read in the 10-Q

PAD Aviation’s creditors do not have recourse to the general credit of the Company, and its assets are not available to satisfy obligations of the Company’s other subsidiaries. The Company has no contractual obligation to provide financial support beyond amounts recognized in the condensed consolidated financial statements.

Read in the 10-Q

The change in goodwill during the nine months ended September 30, 2026 was as follows (in thousands): Balance at December 31, 2025 $11,549 Increase related to PAD Aviation 6,466 Balance at September 30, 2026 $18,015 Acquired intangible assets as of September 30, 2026, which only related to the Company’s 2026 PAD Aviation investment, consisted of the following (in thousands): September 30, 2026 Weighted Average Gross Amount Accumulated Amortization Carrying Value

Read in the 10-Q

Substantially all of the Company’s tangible long-lived assets are located in the United States.

Read in the 10-Q

On July 1, 2026, we completed a strategic investment in PAD Aviation, a Germany-based private aviation operator, through which we acquired a minority interest in PAD Aviation. We expect the investment in PAD Aviation will enable us to expand our aviation transportation capabilities and support the future development of our organ retrieval and logistics services in Europe.

Read in the 10-Q

Prior to our investment in PAD Aviation, PAD Aviation derived its revenue primarily from charter services. We expect PAD Aviation to continue generating revenue from these operations, which will be recorded within service revenue. During the three and nine months ended September 30, 2026, service revenue of $9.4 million was generated from PAD Aviation’s charter services and was unrelated to transplant services.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 5, 2026 against Item 1A of the 10-K filed Feb 24, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:Investing in our common stock involves a high degree of risk. For a detailed discussion of the risks that affect our business, please refer to the section titled “Item 1A. Risk Factors” in our 2025 Form 10-K.

Read in the 10-Q

1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 24, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 27, 2025

transplant logistics ×3experience disruptions ×3government shutdowns ×3opportunistically evaluate ×2evaluate acquisitions ×2new long-term ×2long-term global ×2global headquarters ×2additional facilities ×2expected benefits ×2new facilities ×2management attention ×2emerging technologies ×2continuing appropriations ×2extensions act ×2government shutdown ×2
Where each one is used
  • transplant logistics: •the costs associated with maintaining and growing our transplant logistics capabilities, including by means of attracting, training and retaining pilots, and the acquisition, maintenance, or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or...
  • experience disruptions: headquarters, which we expect to move into on or before January 1, 2028, will meet these increased requirements but we may encounter technical challenges to increasing the scale at which we manufacture the OCS, including with respect to material procurement and quality control and assurance. An increase in...
  • government shutdowns: Our aircraft operations are affected by factors beyond our control, including air traffic congestion at airports, air traffic control inefficiencies and staffing shortages, increased and changing security measures, changing regulatory and governmental requirements, and new or changing travel-related taxes. For...
  • opportunistically evaluate: Our financial results may fluctuate from quarter to quarter due to a number of factors, including the availability of donor organs for transplantation and transplant center surgeons, which is unpredictable and could impact the volume of transplant procedures performed at transplant centers using the OCS and demand...
  • evaluate acquisitions: Our financial results may fluctuate from quarter to quarter due to a number of factors, including the availability of donor organs for transplantation and transplant center surgeons, which is unpredictable and could impact the volume of transplant procedures performed at transplant centers using the OCS and demand...
  • new long-term: Our efforts to grow our business may be costlier than we expect. If our operating and capital expenditures are greater than we expect and if our revenue growth is not sufficient to support these expenditures, we will not be able to sustain profitability. We expect our operating and capital expenditures will...
  • long-term global: Our efforts to grow our business may be costlier than we expect. If our operating and capital expenditures are greater than we expect and if our revenue growth is not sufficient to support these expenditures, we will not be able to sustain profitability. We expect our operating and capital expenditures will...
  • global headquarters: Our efforts to grow our business may be costlier than we expect. If our operating and capital expenditures are greater than we expect and if our revenue growth is not sufficient to support these expenditures, we will not be able to sustain profitability. We expect our operating and capital expenditures will...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

3 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
Furthermore, our ability to utilize our NOLs or credits is conditioned upon our maintaining profitability and generating U.S. federal and state taxable income. As described above, prior to 2024, we incurred significant net losses since inception; and therefore, we do not know whether we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards. Under the Tax Cuts and Jobs Act, or TCJA, NOLs arising in taxable years beginning after December 31, 2017 will not be subject to expiration. In addition, the deduction for NOLs in any taxable year is...
In the 10-K filed Feb 27, 2025
We have a limited history of providing aviation transportation services and we continue to depend on certain members of the former management team of Summit for the successful operation and integration into our NOP services offering. Even if we are able to utilize the Bridge to Life Assets and fully realize the benefits of our acquisition of Summit, we may not realize the expected
In the 10-K filed Feb 27, 2025
•the costs incurred in our efforts to operate and grow our NOP, including the costs and timing of growing our logistics capabilities, inclusive of acquiring and maintaining current and additional aircraft for our aviation transportation services;
In the 10-K filed Feb 27, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.